Abstract FDA’s proposed mandatory Generally Recognized as Safe (GRAS) notification rule would create both transitional and recurring costs for companies relying on the GRAS pathway. In its Preliminary Regulatory Impact […] Read More >>
Abstract Hazard Analysis and Critical Control Point (HACCP) is a preventive food safety system designed to identify biological, chemical and physical hazards and establish controls at points where those hazards […] Read More >>
Abstract The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) represented the most significant expansion of the U.S. Food and Drug Administration’s authority over cosmetics since the Federal Food, Drug, […] Read More >>
Abstract L-theanine has become one of the most widely used functional ingredients in beverages formulated to support focus, relaxation, and cognitive wellness. As manufacturers continue to expand into ready-to-drink (RTD) […] Read More >>
At a Glance A GRAS dossier is often viewed as a regulatory submission prepared solely to support commercialization in the United States. In reality, a well-developed GRAS dossier can become […] Read More >>
At a Glance A well-prepared self-affirmed GRAS dossier may already contain much of the scientific information needed to support an FDA GRAS notice. However, converting an existing dossier for FDA […] Read More >>
At a Glance Live Biotherapeutic Products (LBPs) are transforming therapeutic development, with clinical programs expanding across gastrointestinal disorders, metabolic disorders, immunology, oncology, and rare conditions. Unlike conventional pharmaceutical Read More >>
Abstract Probiotics and postbiotics are both increasingly used in microbiome-focused health products, but the regulatory and clinical considerations surrounding them can differ substantially. Probiotics depend on live microorganisms, making strain [&hellip Read More >>
At a Glance While many commercially available probiotics have a well-documented history of safe use in healthy populations, clinical trials evaluating live biotherapeutic products (LBPs) or probiotic dietary supplements are […] Read More >>
Abstract Introduction Developing a proprietary blend can create an important regulatory question: if every component is already Generally Recognized as Safe (GRAS), can the ingredients be combined under one existing […] Read More >>
Abstract Live Biotherapeutic Products (LBPs) are biological products that contain live organisms, are applicable to the prevention, treatment, or cure of a human disease or condition, and are not vaccines. […] Read More >>
Abstract Although the proposed rule has been quieter than many expected, recent FDA communications confirm that Front-of-Package (FOP) nutrition labelling remains very much on the agency’s agenda. Here’s what has […] Read More >>
Abstract For ingredient manufacturers expanding internationally, achieving Generally Recognized as Safe (GRAS) status in the United States is often viewed as a significant regulatory milestone. However, GRAS does not authorize […] Read More >>
Abstract Synbiotics represent an increasingly sophisticated approach to microbiome-focused products by combining live microorganisms with substrates designed to support beneficial microbial activity. However, regulatory classification and evidence requirem Read More >>
Abstract Postbiotics are emerging as a significant new category of microbiome-focused products, offering potential advantages over traditional probiotics through improved stability, simplified manufacturing, and greater formulation flexibility. However, de Read More >>
Abstract U.S. GRAS status is an important safety milestone, but it does not authorize an ingredient for sale in Canada. Instead, Health Canada evaluates ingredients under its own regulatory framework, […] Read More >>
Abstract Good Manufacturing Practices are fundamental to product quality in both the Canadian Natural Health Product and U.S. dietary supplement industries. However, the requirements are not interchangeable. In the United […] Read More >>
Regulatory and oversight concern around AI hallucinations is not centered only on intentional misuse, but on the introduction of unverifiable, unsupported, or fabricated information into regulated workflows. As organizations increasingly […] Read More >>
On February 2, 2026, the FDA’s revised Quality Management System Regulation (QMSR) officially became effective, replacing the long-standing Quality System (QS) Regulation framework under 21 CFR Part 820. While the […] Read More >>
Artificial intelligence is changing the way regulators evaluate medical devices, particularly where software functionality influences clinical decision-making or adapts over time. While software regulation is not new, machine learning introduces […] Read More >>